Resverlogix, Emerald Logic complete collaborative research program

Mar 4 2015

Emerald Logic FACET software generates predictive models and identifies novel variables driving RVX-208 drug efficacy, safety and reduced MACE incidence

Resverlogix Corp. (TSX:RVX) (the "Company") today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE. The objective of this collaborative program was to develop quantitative models and identify variables that contribute to drug response, and the incidence of major adverse cardiac events (MACE).

"We are delighted to work with the Resverlogix team in this exciting area of epigenetic drug development and BET inhibition," stated Mr. Patrick Lilley, president and chief executive officer of Emerald Logic Inc. "Resverlogix's clinical dataset, consisting of patients treated with the first BET inhibitor to be tested in the clinic, provides an unprecedented opportunity to examine factors contributing to drug efficacy, major adverse cardiac events and safety for this drug class."

The complete dataset, containing approximately 650,000 data points, was analyzed using Emerald Logic's FACET software. This unique approach combines medical history, epidemiology, demographics, patient vital signs, and clinical lab measures in order to identify explanatory factors for efficacy and adverse events and to produce discriminatory models without bias or guidance. "Our clinical dataset is a powerful repository that can be mined to understand variables that drive vascular risk and drug response," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "Emerald Logic has completed many healthcare projects and the computational power of its software has produced accurate and insightful results that are outside the capabilities of currently practiced methods," Mr. McCaffrey added.

The collaboration generated multiple proprietary models and deduced both binary and continuous variables, previously unidentified, that contribute to drug efficacy, adverse events and most importantly to the observed reduction in MACE incidence in response to treatment with RVX-208. The Company plans to file new intellectual property surrounding these variables and algorithms and intends to integrate and assess them in upcoming clinical trials for the purpose of patient enrichment and safety monitoring. "With the addition of every new clinical data point from upcoming trials, the models will continue to evolve and strengthen their predictive ability for future patient screening and targeting," stated Mr. McCaffrey. "The variables identified have already provided Resverlogix with novel avenues for exploration in patients with cardiovascular disease and diabetes mellitus, and in the mitigation of adverse events."